idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
Tuberculosis (TB) is the world’s biggest infectious disease killer with multidrug-resistant TB (MDR-TB) posing a particular threat to global health. A study led by the Swiss Tropical and Public Health Institute (Swiss TPH) shows that resistance to the new MDR-TB treatment regimen recently recommended by the World Health Organization is already spreading between patients. The findings, published yesterday in the renowned New England Journal of Medicine, highlight the urgent need for better surveillance and infection control to counteract the rise in antimicrobial resistance.
Multidrug-resistant TB is a major concern
More than 10 million people fall sick with tuberculosis (TB) every year. The disease remains the world’s biggest infectious disease killers with an estimated 1.25 million annual deaths. The disease is still found in every country, but certain regions, such as India, Central Asia and Southern Africa, bear a particularly high burden. Multidrug-resistant TB (MDR-TB) continues to pose a major public health threat, adding to the growing concern of rising antimicrobial resistance.
The traditional treatment regimen for MDR-TB is lengthy, expensive, and comes with severe adverse event. In 2022, the World Health Organization (WHO) endorsed a new 6-month regimen – the BPaL(M) –, based on evidence of its improved safety and efficacy from numerous clinical studies, including TB-PRACTECAL.
Monitoring the implementation of a new treatment regimen
“While this new regimen is a game changer for patients suffering from MDR-TB, we knew that it will be difficult to outsmart Mycobacterium tuberculosis, the bacteria causing TB,” said Sébastien Gagneux, Head of the Department Medical Parasitology and Infection Biology at Swiss TPH and senior author of the study. “It was therefore crucial to study how the TB bacteria would react to the global roll-out of this new regimen.”
A study led by Swiss TPH in collaboration with the National Centre for Tuberculosis and Lung Diseases in Tbilisi, Georgia, published yesterday in the renowned New England Journal of Medicine now examined in detail whether resistance to the drugs in the new regimen has already emerged since its introduction, and whether this resistance is transmitting between patients.
Over a quarter of resistant strains result from transmission between patients
The researchers analysed the genomes of close to 90,000 M. tuberculosis strains from Georgia and many other countries around the world. They identified a total of 514 strains that were resistant to TB drugs, including both the old and the new treatment regimens. These highly drug-resistant strains were found in 27 countries across four continents.
Alarmingly, 28% of these strains were transmitted directly from one patient to another. “We already had anecdotal evidence of resistance emerging to the new regimen, but we did not know to what extent transmission was responsible for the spread of these highly drug-resistant strains,” said Galo A. Goig, postdoctoral collaborator at Swiss TPH and first author of the study.
“The good news is that the total number of these cases is still low. However, the fact that more than a quarter of these highly drug-resistant cases are due to patient-to-patient transmission, only two years after WHO endorsed the new regimen, is worrying,” added Goig.
Call for better surveillance and infection control
These findings have important implications for public health policy and interventions. “These new drugs have taken many years to develop, and to prevent drug resistance from emerging, it is essential to combine the deployment of these new regimens with robust diagnostics and surveillance systems,” said Chloé Loiseau, postdoctoral collaborator at Swiss TPH and co-author of the paper.
The authors emphasize the need for improved diagnostic tools, better infection control and robust surveillance systems to curb the spread of these highly drug-resistant strains, and to safeguard the efficacy of the new treatment regimen.
Tackling antimicrobial resistance
While there are already new TB drugs in the pipeline, experts worry that M. tuberculosis will continue to find ways to evade new drugs. “The example of these highly drug-resistant TB strains further illustrates that antimicrobial resistance is one of the most critical threats to global health today,” said Gagneux. “We must stay ahead in this constant race between drug development and bacterial resistance, and take proactive steps to prevent a ‘post-antibiotic era’ for TB and other diseases.”
About the study
The study was published yesterday in the New England Journal of Medicine. Swiss TPH led the study in collaboration with the National Center for Tuberculosis and Lung Diseases (NCTLD) in Tbilisi, Georgia. The work was supported by the Swiss National Science Foundation (SNSF) and the European Research Council (ERC).
https://www.nejm.org/doi/full/10.1056/NEJMc2404644
About tuberculosis
Tuberculosis (TB) is an infectious disease caused by Mycobaterium tuberculosis. TB is spread from person to person through the air. Symptoms of the disease include coughing, chest pain, weight loss, fever and night sweats. Multidrug-resistant tuberculosis (MDR-TB) is a form of TB caused by bacteria that do not respond to the two most effective first-line TB drugs. Only about 2 in 5 people with MDR-TB accessed treatment in 2022.
Swiss TPH’s contribution to the fight against TB
Swiss TPH is committed to alleviate TB-related suffering, working on five continents, from basic research to health systems strengthening. Activities include the investigation of the host-pathogen interaction, of the evolution of antibiotic resistance and of the host immune responses to infection and evaluations of TB initiatives and programmes. Swiss TPH also conducts clinical trials of new TB diagnostics, drugs and vaccines in collaboration with our long-term partners at the Ifakara Health Institute (IHI) in Tanzania and the National Center for Tuberculosis and Lung Diseases (NCTLD) in Georgia.
Prof. Dr. Sébastien Gagneux, Head, Department of Medical Parasitology and Infection Biology, Swiss TPH, sebastien.gagneux@swisstph.ch, +41 61 284 8369
https://www.nejm.org/doi/full/10.1056/NEJMc2404644
https://www.swisstph.ch/en/news/news-detail/news/tuberculosis-strains-resistant-...
By analysing the genomes of close to 90,000 TB strains from around the world, scientists from Swiss ...
Joachim Pelikan/Swiss TPH
Joachim Pelikan/Swiss TPH
Merkmale dieser Pressemitteilung:
Journalisten
Biologie, Medizin
überregional
Forschungsergebnisse
Englisch
By analysing the genomes of close to 90,000 TB strains from around the world, scientists from Swiss ...
Joachim Pelikan/Swiss TPH
Joachim Pelikan/Swiss TPH
Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.
Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).
Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.
Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).
Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).
